A5084881385- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- CAR-T cell therapy research
- Genetic factors in colorectal cancer
- Acute Lymphoblastic Leukemia research
- Radiomics and Machine Learning in Medical Imaging
- Chronic Myeloid Leukemia Treatments
- Gastrointestinal Tumor Research and Treatment
Novartis (United States)
2015-2024
The clinical application of PD-L1 immunohistochemistry (IHC) testing is complicated by the availability multiple IHC assays, scoring algorithms, and cutoffs. This study assessed analytical comparability three commercially available assays two algorithms used to assess status in gastric cancer (GC) samples.
2625 Background: The clinical application of programmed death-ligand 1 (PD-L1) immunohistochemistry is complicated by multiple available assays and different testing platforms, scoring algorithms, cut-offs applied. This study assessed the analytical comparability three commercially PD-L1 (28-8, 22C3, SP263) two algorithms used in gastric cancer (GC). Methods: Serial sections 100 procured GC samples, selected 28-8 assay to represent dynamic range expression, were stained with vitrodiagnostic...